HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 01-07-2005, 05:59 AM   #1
*_KathySC_*
Guest
 
Posts: n/a
RICHMOND, Va., Sep 8, 2004 (BUSINESS WIRE) -- Insmed, Inc. (NASDAQ: INSM) announced today the initiation of a Phase I clinical study for the company's novel anti-tumor agent, recombinant human Insulin-Like Growth Factor Binding Protein-3 (rhIGFBP-3). The Phase I clinical study is an open-label, dose-escalation study designed to evaluate for the first time in humans, the safety, tolerability and pharmacokinetics of a single intravenous dose of rhIGFBP-3. The primary goal of this 30 patient study is to identify the appropriate dose of rhIGFBP-3 for a planned Phase II clinical trial in 2005.

"The FDA's approval of growth factor inhibitors to treat cancer not only validates this approach but also encourages the development of other growth factor inhibiting agents, such as rhIGFBP-3" noted Laura Shiry, Ph.D., Insmed's head oncology scientist. "Our research shows that rhIGFBP-3 is an essential regulator of the IGF signaling pathway, which is known to be permissive to tumor growth while facilitating other tumor-promoting pathways, including EGF and VEGF. We have what we believe to be solid preclinical evidence demonstrating that rhIGFBP-3 could provide substantial benefit in treating a number of human cancers, including those of the breast, prostate, colon and lung."

The Role of rhIGFBP-3 in the Tumor Growth

Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) is a naturally occurring protein in the body whose normal role is to regulate the activity of Insulin-Like Growth Factor-I (IGF-I). Although the IGF-I is critical for normal growth and metabolism, aberrant signalling through this pathway is closely linked to the abnormal and unregulated growth of a variety of tumors. Blocking tumor-associated IGF signaling has been proven to prevent tumor growth in a variety of preclinical models. In preclinical models, rhIGFBP-3 has demonstrated efficacy in preventing tumor formation and progression. Based on these findings, Insmed is developing rhIGFBP-3 as a novel anti-IGF-I treatment for cancer.

About Insmed

Insmed is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding planned clinical trial design and goals, our regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates, the FDA may interpret the results of our studies differently than we have, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.

SOURCE: Insmed, Inc.

Insmed, Inc.
Baxter Phillips, III, 804-565-3041
Fax: 804-565-3510
bphillips@insmed.com

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.

Copyright © 2004 Business Wire. All rights reserved.

News Provided by COMTEX
  Reply With Quote
Old 01-10-2005, 09:44 AM   #2
Christine MH
Guest
 
Posts: n/a
Although it is not strictly anti-HER2, it could be useful for us since one article looking at the common traits of HER2 cancers noted that they tended to have too little insulin growth factor binding protein.
  Reply With Quote
Old 02-11-2005, 01:44 PM   #3
anonymous
Guest
 
Posts: n/a
Ladies please beware that RBGF (the growth factor given to cows to increase milk production) causes an increase in IGF-1. Buy only ORGANIC milk untreated with this hormone please. We are not even sure if they are correctly labeling the milk. Monsanto is a giant phar. cie that makes this RBGF and is rumored to use some unlawful practices to cover up the whole thing.
  Reply With Quote
Old 02-16-2005, 03:11 AM   #4
Christine MH
Guest
 
Posts: n/a
I have looked into this matter and what I found was a 2001 letter in the Journal of the National Cancer Institute highlighting this as a concern:
http://jncicancerspectrum.oupjournals.org/...l/jnci;93/3/238
but also the U.S. FDA's arguments arguing that this was not a problem:
http://www.fda.gov/cvm/index/bst/RBRPTFNL.htm

The European Union has banned the use of milk-production producing hormones. Reports at the time indicate that this ban was initially put in place out of concerns that consumers would stop milk out of a concern over the hormones and because it would undermine agricultural policy. When a permanent ban was imposed, according to a press report the relevant committee "concluded that the risk to human health from drinking milk from rBST-treated cows was likely to be extremely small but could not
be ruled out entirely without further studies. The Committee also concluded that the treatment of dairy cows with rBST is associated with welfare problems, notably decreased body condition, an increased risk of mastitis, lameness and injection site lesions." It was primarily these animal welfare concerns that led to the product being banned. I suspect, too, that there is something to fears about consumer resistance to hormones in food, because I live in England and after the mad cow crisis people are very skittish about any unnatural food practices, no matter what the science says.

I just thought it was important to point out that there is some doubt over the matter.
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:32 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter